The neutralizing antibody HGF or IL-6 has been used to successfully reverse the stem cell viability of CD24+ HCC cells in vitro and in vivo through the HGF/C-MET/STAT3 or IL6/IL6R/STAT3 signaling pathways (138). This evidence concerns the gene HGF and hepatocellular carcinoma.